Recent clinical evidence has demonstrated that only a minority of patients with CRC demonstrated significant responses to PD-1 blockade (Lynch and Murphy, 2016), and these solitary patient with CRC who had responded to the PD-1 inhibitor were dMMR (also known as MSI) (Aguiar et al., 2015). The gene discussed is PDCD1; the disease is colorectal carcinoma.